Gene Expression Profiles in Stage II and III Colon Cancer. Application of a 128-gene signature
Purpose: A 128-gene signature has been proposed to predict poor outcomes in patients with stage II and III colorectal cancer. In the present study we aimed to validate this previously published 128-gene signature on external and independent data from patients with stage II and III colon cancer.
Provenance — who produced it, who reused it
Linked to 32 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- Machine learning-based integration develops an immune-derived ln... 2022 · 914 cites
- CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon C... 2016 · 480 cites
- Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF... 2018 · 276 cites
- Integrative analysis from multi-center studies identities a cons... 2021 · 213 cites
- Tumor-selective proteotoxicity of verteporfin inhibits colon can... 2015 · 192 cites
- The long non-coding RNA CYTOR drives colorectal cancer progressi... 2018 · 162 cites
- The Long Noncoding RNA MALAT-1 is A Novel Biomarker in Various C... 2016 · 112 cites
- An integrative analysis reveals functional targets of GATA6 tran... 2013 · 81 cites
24 further papers cite this accession but reuse could not be confirmed.
Deep data QC
metadata only · no data-level QC for this typeStandardized, field-standard QC computed by touching the data — every metric states how it was obtained
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0 · provisional — verify independently